

©2024 Celgene Corporation a Bristol Myers Squibb company.
Abecma® is a trademark of Celgene Corporation.



ABECMA® (IDECABTAGENE VICLEUCEL)

P A T I E N T C A R D

ABECMA® (IDECABTAGENE VICLEUCEL)

ABECMA[®]

(IDECABTAGENE VICLEUCEL)

PATIENT CARD



Have this card with you at all times. Show it to any doctor/healthcare provider who sees you, including in conditions of emergency.

Tell any healthcare provider who sees you that you are being treated with Abecma.

For at least 4 weeks after receiving Abecma, you should plan to stay close (within 2 hours of travel) to the location where you received treatment.

This patient card, format and its content have been approved by the ministry of health on October 2024

2012-IL-2400006 10/24

I have been treated with ABECMA[®]

Important Contact Information (PRINT)

My Name:

Name of Abecma Treating Physician:

Office/Hospital Phone Number:

After-hours Phone Number:

Hospital Name:

Date of Abecma Infusion (DD/MM/YYYY):

Batch Number:

Information for the Healthcare Provider

This patient has received Abecma CART cell therapy, a B-cell maturation antigen-directed genetically modified autologous T cell immunotherapy.

Following treatment with Abecma, cytokine release syndrome (CRS) and/or neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), may occur, which may be fatal or life-threatening. Cytokine release syndrome may involve any organ system. Other adverse reactions may include cytopenias, hypogammaglobulinemia and infections.

Contact patient's Abecma treating physician immediately for further information.

Please see Abecma's Prescribing Information and Patient leaflet on the Israeli Ministry of Health website: <https://israeldrugs.health.gov.il/#!/byDrug>

This patient card, format and content have been approved by the ministry of health on October 2024.

2012-IL-2400006 10/24

Side effects can be reported to the Ministry of Health by clicking on the "Reporting side effects following drug treatment" link found on the Ministry of Health homepage (www.health.gov.il) that directs you to the online form for reporting side effects, or through the following link: <https://sideeffects.health.gov.il>

You may also report side effects to BMS by phone: 1809-388054 (a toll-free number) or email: MedInfo.Israel@bms.com

Information for Patients

Abecma may cause side effects that are severe or life-threatening.

Call your Abecma treating physician or go to the emergency room/department immediately if any of the following symptoms appear:

Neurologic Adverse Reactions

The following may be symptoms of ICANS:

- Confusion
- Difficulty with memory
- Difficulty speaking or slowed speech
- Difficulty understanding speech
- Loss of balance or coordination
- Disorientation
- Being less alert (decreased consciousness) or excessive sleepiness
- Loss of consciousness
- Delirious
- Fits (seizures)

Also, shaking, weakness with loss of movement on one side of the body, tremor, slow movements, or stiffness, which may be symptoms of parkinsonism.

Cytokine Release Syndrome (CRS)

- Fever
- Chills
- Difficulty breathing
- Dizziness or light-headedness
- Nausea
- Headache
- Fast heartbeat
- Low blood pressure
- Fatigue

Infections

- Fever
- Chills or shivering
- Cough
- Shortness of breath
- Rapid breathing
- Rapid pulse

To obtain additional copies of this Patient Card, please contact BMS Israel by phone 03-5231021, fax 03-9226896 or email: Office_IL@bms.com